Agios Medical Booth

American Society of Clinical Oncology Annual Meeting 2020

IDH Mutations in Cancer

At Agios, our lead oncology programs are focused on cancers with a mutated isocitrate dehydrogenase (IDH) protein. IDH mutations occur in a wide range of blood and solid tumor cancers, including acute myeloid leukemia (AML), cholangiocarcinoma and glioma. Normally, IDH enzymes help to break down nutrients and generate energy for cells. When mutated, IDH creates a molecule that alters the cells’ genetic programming, and instead of maturing, the cells remain primitive and proliferate quickly. Agios believes that targeting mutated IDH may have the potential to benefit the subset of patients with tumors that carry IDH mutations.

IDH Inhibition Mechanism of Action

IDH Mutation Testing

Explore the role of IDH mutations in mIDH-positive cancers and the importance of molecular profiling.

Learn More

 

Find out more about IDH mutations in hematologic malignancies and solid tumors.

ExploreIDH.com

Ongoing Clinical Trials

INDIGO

Phase 3 Study of Vorasidenib in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation

Download INDIGO Trial Card
AGILE

Phase 3 Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated AML with an IDH1 Mutation

Download AGILE Trial Card
Myelodysplastic Syndrome (MDS) Phase 1 Study

Ongoing Phase 1 Expansion Arm Evaluating Ivosidenib in Adult Patients with Relapsed or Refractory MDS with an IDH1 Mutation

Download MDS Trial Card

View Our Pipeline

Learn More about Our Clinical Programs

ASCO 2020 Presentations and Posters

All oral and poster presentations will be available on demand for registered meeting attendees on the ASCO conference website beginning on May 29 at 8:00 a.m. ET.

Oral Presentations

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population
Abstract: 2804

Phase Ib/II Study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor Venetoclax +/-azacitidine in IDH1-mutated hematologic malignancies (Investigator-sponsored trial)
Abstract: 7500

Poster Presentations

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation
Abstract: TPS2574

IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study
Abstract: 4576

Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
Abstract: 7521

Patient Resources

Fast Facts on Cholangiocarcinoma

Two-page information sheet on cholangiocarcinoma for patients and their supporters.

Download Information Sheet on Cholangiocarcinoma

Contact Us

Medical Information Inquiries
  • Agios Medical Information Call Center
  • Monday – Friday 7:00am – 6:00pm CT
  • with Urgent After Hours

IVO-US-0504